Skip to content

Pergamum AB Announces Ownership Restructuring

STOCKHOLM – May 28, 2015. Today, Pergamum AB announces that Karolinska Development AB (STO: KDEV), and The Foundation for Baltic and East European Studies , have divested their entire shareholding in Pergamum AB, which is a company developing products in the field of specialty dermatology and biosurgery, to a consortium lead by Midroc New Technology AB and Rosetta IV SARL.

“We are thankful for the financial involvement and stewardship that Karolinska Development and The Foundation for Baltic and East European Studies have demonstrated in Pergamum since the inception of our technologies. Without their investments and support, our company would not have reached this crossroad,” said Jonas Ekblom, President of Pergamum. ”Pharmaceutical R&D is a highly time- and capital-demanding pursuit; it is important to recognize that ownership configurations need to be occassionally optimized as a consequence of strategic repositioning. I am very excited about the possibilities that this new shareholder’s consortium will provide for Pergamum. It will allow us to recruit the necessary funds in order to bring Pergamum to the ensuing inflection points of value.”

As part of the agreement, KD Investments AB, a holding company of Karolinska Development AB, as well as The Foundation for Baltic and East European Studies, will transfer their entire shareholdings in Pergamum to the consortium in an earn-out agreement. No further financial details on this transaction will be disclosed.

For further information, please contact:

Jonas Ekblom, President, Pergamum AB
Phone: +1-714-369-0478, e-mail:

About Pergamum AB

Pergamum is a biopharmaceutical company specialized in the development of therapeutic peptides for local application in infections and wounds. The company’s vision is to develop a portfolio of unique development programs representing high medical value that ultimately, through global partnerships, will result in first-in-class and first-in-category products. The current development pipeline includes several therapeutic peptides of which three programs are in clinical development, with potential for use in several medical applications. Please visit our web site: